Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines

Cancer Research

Volumn 60, Issue 7, 2000, Pages 1800-1804

  Tsao, Hensin ^a   Zhang, Xue ^a,b   Fowlkes, Kianna ^a   Haluska, Frank G ^a,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b CHINA MEDICAL UNIVERSITY   (China)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; PHOSPHATIDYLINOSITOL 3 KINASE;

ARTICLE; COLONY FORMATION; CONTROLLED STUDY; GENE MUTATION; GLIOMA CELL; HUMAN; HUMAN CELL; MELANOMA; ONCOGENE RAS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; SKIN METASTASIS; TUMOR SUPPRESSOR GENE;

ALTERNATIVE SPLICING; AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; BRAIN NEOPLASMS; EXONS; FRAMESHIFT MUTATION; GENE DELETION; GENES, RAS; GENES, TUMOR SUPPRESSOR; GLIOMA; HUMANS; MELANOMA; MELANOMA, EXPERIMENTAL; MICE; MUTATION; PHOSPHORIC MONOESTER HYDROLASES; POINT MUTATION; PROTO-ONCOGENE PROTEINS P21(RAS); PTEN PHOSPHOHYDROLASE; SEQUENCE DELETION; SKIN NEOPLASMS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EID: 0034085811     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Haluska, F. G., and Hodi, F. S. Molecular genetics of familial cutaneous melanoma. J. Clin. Oncol., 16: 670-682, 1998.
2. Carr, J., and Mackie, R. M. Point mutations in the N-ras oncogene in malignant melanoma and congenital naevi. Br. J. Dermatol., 131: 72-77, 1994.
3. van Elsas, A., Zerp, S. F., van der Flier, S., Kruse, K. M., Aarnoudse, C., Hayward, N. K., Ruiter, D. J., and Schrier, P. I. Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma. Am. J. Pathol., 149: 883-893, 1996.
4. Wagner, S. N., Ockenfels, H. M., Wagner, C., Hofler, H., and Goos, M. Ras gene mutations: a rare event in nonmetastatic primary malignant melanoma. J. Investig. Dermatol., 104: 868-871, 1995.
5. Ball, N. J., Yohn, J. J., Morelli, J. G., Norris, D. A., Golitz, L. E., and Hoeffler, J. P. Ras mutations in human melanoma: a marker of malignant progression. J. Investig. Dermatol., 102: 285-290, 1994.
6. Herlyn, M., and Satyamoorthy, K. Activated ras: yet another player in melanoma? Am. J. Pathol., 149: 739-744, 1996.
7. Schuchter, L. M., Haluska, F. G., Fraker, D., Elenilsas, R., and Wolfe, J. Skin. In: M. D. Abeloff, J. O. Armitage, A. S. Lichter, and J. E. Niederhuber (eds.), Clinical Oncology, Ed. 2, pp. 1317-1350. New York: Churchill Livingstone, 2000.
8. Chin, L., Pomerantz, J., Polsky, D., Jacobson, M., Cohen, C., Cordon-Cardo, C., Horner, J. W., II, and DePinho, R. A. Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. Genes Dev., 11; 2822-2234, 1997.
9. Tsao, H., Zhang, X., Benoit, E., and Haluska, F. G. Identification of PTEN/MMACI alterations in uncultured melanomas and melanoma cell lines. Oncogene, 16: 3397-3402, 1998.
10. Guldberg, P., thor Straten, P., Birck, A., Ahrenkiel, V., Kirkin, A. F., and Zeuthen, J. Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res., 57: 3660-3663, 1997.
11. Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., Bigner, S. H., Giovanella, B. C., Ittmann, M., Tycko, B., Hibshoosh, H., Wigler, M. H., and Parsons, R. PTEN, a putative tyrosine phosphatase gene mutated in human brain, breast and prostate cancer. Science (Washington DC), 275: 1943-1947, 1997.
12. Steck, P. A., Pershouse, M. A., Jasser, S. A., Yung, W. K. A., Lin, H., Ligon, A. H., Langford, L. A., Baumgard, M. L., Hattier, T., Davis, T., Frye, C., Hu, R., Swedlund, B., Teng, D. H. F., and Tavtigan, S. V. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat. Genet., 15: 356-362, 1997.
13. Myers, M. P., Pass, I., Batty, I. H., Van der Kaay, J., Stolarov, J. P., Hemmings, B. A., Wigler, M. H., Downes, C. P., and Tonks, N. K. The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc. Natl. Acad. Sci. USA, 95: 13513-13518, 1998.
14. Maehama, T., and Dixon, J. E. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J. Biol. Chem., 273: 13375-13378, 1998.
15. Stambolic, V., Suzuki, A., de la Pompa, J. L., Brothers, G. M., Mirtsos, C., Sasaki, T., Ruland, J., Penninger, J. M., Siderovski, D. P., and Mak, T. W. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell. 95: 29-39, 1998.
16. Podsypanina, K., Ellenson, L. H., Nemes, A., Gu, J., Tamura, M., Yamada, K. M., Cordon-Cardo, C., Catoretti, G., Fisher, P. E., and Parsons, R. Mutation of Pten/ Mmac1 in mice causes neoplasia in multiple organ systems. Proc. Natl. Acad. Sci. USA, 96: 1563-1568, 1999.
17. Di Cristofano, A., Pesce, B., Cordon-Cardo, C., and Pandolfi, P. P. Pten is essential for embryonic development and tumour suppression. Nat. Genet., 19: 48-55, 1998.
18. Boughdady, I. S., Kinsella, A. R., Haboubi, N. Y., and Schofield, P. F. K-ras gene mutations in adenomas and carcinomas of the colon. Surg. Oncol., I: 275-282, 1992.
19. Burmer, G. C., Rabinovitch, P. S., and Loeb, L. A. Analysis of c-Ki-ras mutations in human colon carcinoma by cell sorting, polymerase chain reaction, and DNA sequencing. Cancer Res., 49: 2141-2146, 1989.
20. Burmer, G. C., and Loeb, L. A. Mutations in the KRAS2 oncogene during progressive stages of human colon carcinoma. Proc. Natl. Acad. Sci. USA, 86: 2403-2407, 1989.
21. Vogelstein, B., Fearon, E. R., Hamilton, S. R., Kern, S. E., Preisinger, A. C., Leppert, M., Nakamura, Y., White, R., Smits, A. M., and Bos, J. L. Genetic alterations during colorectal-tumor development. N. Engl. J. Med., 319: 525-532, 1988.
22. Smit, V. T., Boot, A. J., Smits, A. M., Fleuren, G. J., Cornelisse, C. J., and Bos, J. L. KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucleic Acids Res., 16: 7773-7782, 1988.
23. Wang, Z. J., Taylor, F., Churchman, M., Norbury, G., and Tomlinson, I. Genetic pathways of colorectal carcinogenesis rarely involve the PTEN and LKB1 genes outside the inherited hamartoma syndromes. Am. J. Pathol., 153: 363-366, 1998.
24. Okami, K., Wu, L., Riggins, G., Cairns, P., Goggins, M., Evron, E., Halachmi, N., Ahrendt, S. A., Reed, A. L., Hilgers, W., Kern, S. E., Koch, W. M., Sidransky, D., and Jen, J. Analysis of PTEN/MMAC1 alterations in aerodigestive tract tumors. Cancer Res., 58: 509-511, 1998.
25. Zhou, X. P., Li, Y. J., Hoang-Xuan, K., Laurent-Puig, P., Mokhtari, K., Longy, M., Sanson, M., Delattre, J. Y., Thomas, G., and Hamelin, R. Mulational analysis of the PTEN gene in gliomas: molecular and pathological correlations. Int. J. Cancer, 84: 150-154, 1999.
26. Ishii, N., Maier, D., Merlo, A., Tada, M., Sawamura, Y., Diserens, A. C. and Van Meir, E. G. Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol., 9: 469-479, 1999.
27. Duerr, E. M., Rollbrocker, B., Hayashi, Y., Peters, N., Meyer-Puttlitz, B., Louis, D. N., Schramm, J., Wiestler, O. D., Parsons, R. Eng, C., and von Deimling, A. PTEN mutations in gliomas and glioneuronal tumors. Oncogene, 16: 2259-2264, 1998.
28. Iolascon, A., Lania, A., Badiali, M., Pession, A., Saglio, G., Giangaspero, F., Miraglia del Giudice, E., Perrotta, S., and Cutillo, S. Analysis of N-ras gene mutations in medulloblastomas by polymerase chain reaction and oligonucleotide probes in formalin-fixed, paraffin-embedded tissues. Med. Pediatr. Oncol., 19: 240-245, 1991.
29. Maltzman, T. H., Mueller, B. A., Schroeder, J., Rutledge, J. C., Patterson, K., Preston-Martin, S., and Faustman, B. M. Ras oncogene mutations in childhood brain tumors. Cancer Epidemiol. Biomark. Prev., 6: 239-243, 1997.
30. Rodriguez-Viciana, P., Warne, P. H., Vanhaesebroeck, B., Waterfield, M. D., and Downward, J. Activation of phosphoinositide 3-kinase by interaction with Ras and by point mutation. EMBO J., 15: 2442-2451, 1996.
31. Rodriguez-Viciana, P., Warne, P. H., Dhand, R., Vanhaesebroeck, B., Gout, I., Fry, M. J., Waterfield, M. D., and Downward, J. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature (Lond.), 370: 527-532, 1994.
32. Rodriguez-Viciana, P., Warne, P. H., Khwaja, A., Marte, B. M., Pappin, D., Das, P.. Waterfield, M. D., Ridley, A., and Downward, J. Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cyloskeleton by Ras. Cell, 89: 457-467, 1997.
33. Ohta, M., Berd, D., Shimizu, M., Hirokazu, N., Cotticelli, M-G., Mastrangelo, M., Shields, J. A., Shields, C. L., Croce, C. M., and Huebner, K. Deletion mapping of chromosome region 9p21-p22 surrounding the DKN2 locus in melanoma. Int. J. Cancer, 65: 762-767, 1996.
34. Furnari, F. B., Lin, H., Huang, H. S., and Cavenee, W. K. Growth suppression of glioma cells by PTEN requires a functional phosphatase catalytic domain. Proc. Natl. Acad. Sci. USA, 94: 12479-12484, 1997.
35. Navarro, P., Valverde, A. M., Benito, M., and Lorenzo, M. Activated Ha-ras induces apoptosis by association with phosphorylated Bcl-2 in a mitogen-activated protein kinase-independent manner. J. Biol. Chem., 274: 18857-18863, 1999.
36. Chi, S., Kitanaka, C., Noguchi, K., Mochizuki, T., Nagashima, Y., Shirouzu, M., Fujita, H., Yoshida, M., Chen, W., Asai, A., Himeno, M., Yokoyama, S., and Kuchino, Y. Oncogenic Ras triggers cell suicide through the activation of a caspase-independent cell death program in human cancer cells. Oncogene, 18: 2281-2290, 1999.
37. Liu, H. S., Chen, C. Y., Lee, C. H., and Chou, Y. I. Selective activation of oncogenic Ha-ras-induced apoptosis in NIH/3T3 cells. Br. J. Cancer. 77: 1777-1786, 1998.
38. Kodaki, T., Woscholski, R., Hallberg, B., Rodriguez-Viciana, P., Downward, J., and Parker, P. J. The activation of phosphatidylinositol 3-kinase by Ras. Curr. Biol., 4: 798-806, 1994.
39. Downward, J., and Weinberg, R. A. Influence of p21ras on phosphatidylinositol turnover. Cold Spring Harbor Symp. Quant. Biol., 5.1: 883-892, 1988.
40. Shayesteh, L., Lu, Y., Kuo, W. L., Baldocchi, R., Godfrey, T., Collins, C., Pinkel, D., Powell, B., Mills, G. B., and Gray, J. W. PIK3CA is implicated as an oncogene in ovarian cancer. Nat. Genet., 21: 99-102, 1999.
41. Franke, T. F., Kaplan, D. R., Cantley, L. C., and Toker, A. Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate. Science (Washington DC), 275: 665-668, 1997.
42. Staal, S. P., Hartley, J. W., and Rowe, W. P. Isolation of transforming murine leukemia viruses from mice with a high incidence of spontaneous lymphoma. Proc. Natl. Acad. Sci. USA, 74: 3065-3067, 1977.
43. Staal, S. P., and Hartley, J. W. Thymic lymphoma induction by the AKT8 murine retrovirus. J. Exp. Med., 167: 1259-1264, 1988.
44. del Peso, L., Gonzalez-Garcia, M., Page, C., Herrera, R., and Nunez, G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science (Washington DC), 278: 687-689, 1997.
45. Brunet, A., Bonni, A., Zigmond, M. J., Lin, M. Z., Juo, P., Hu, L. S., Anderson, M. J., Arden, K. C., Blenis, J., and Greenberg, M. E. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell, 96: 857-868, 1999.
46. Borkhardt, A., Repp. R., Haas, O. A., Leis, T., Harbott, J., Kreuder, J., Hammermann, J., Henn, T., and Lampen, F. Cloning and characterization of AFX, the gene that fuses to MLL in acute leukemias with a t(X:11)(q13;q23). Oncogene, 14: 195-202, 1997.
47. Hillion, J., Le Coniat, M., Jonveaux, P., Berger, R., and Bernard, O. A. AF6q21, a novel partner of the MLL gene in t(6; 11)(q21;q23), defines a forkhead transcriptional factor subfamily. Blood, 90: 3714-3719, 1997.
48. Li, J., Simpson, L., Takahashi, M., Miliaresis, C., Myers, M. P., Tonks, N., and Parsons, R. The PTEN/MMAC1 tumor suppressor induces cell death that is rescued by the AKT/protein kinase B oncogene. Cancer Res., 58: 5667-5672, 1998.